Indian biotech major Biocon has said that it will enter into a partnership with a US-based biotechnology company, Iatrica, to develop drug for the treatment of cancer and infectious diseases. Biocon informed the BSE that it would invest in the US-based firm to co-develop a new class of immunoconjugates for targeted immunotherapy of cancers and infectious diseases based upon Iatrica's technology platform and the company's expertise in drug development. The partnership would push clinical development of innovative biohybrid molecules for targeted immunotherapy and thereby reinforce our shared endeavour to provide effective new treatments for major neoplastic and infectious diseases.
Every time an offender stealthily leaves India to take refuge in another country, the Government of India starts all over again with its strategy of bringing him back to the nation to make him stan More
Helplinelaw can set up your session with quality and experienced lawyers to discuss and resolve your legal matters. You can avail consultation in form of sending questions, phone call or webchat discussion More